Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index; 132 of the 168 sources its claims cite were checked for support.

Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review

Open access
Pardossi, Simone, Fagiolini, Andrea, Cuomo, Alessandro · 2024 · International Journal of Molecular Sciences

Abstract

Brain-derived neurotrophic factor (BDNF) is critical for neuroplasticity, synaptic transmission, and neuronal survival. Studies have implicated it in the pathophysiology of depression, as its expression is significantly reduced in brain areas such as the prefrontal cortex and hippocampus in patients with depression. Our narrative review focuses on the relationship between BDNF, ketamine, and esketamine, specifically by summarizing human studies investigating BDNF variations in patients treated with these two drugs. BDNF plays a pivotal role in neuroplasticity and neurotrophic mechanisms that can be enhanced by traditional antidepressants, which have been shown to increase BDNF levels both peripherally and in targeted brain regions. Ketamine and its S-enantiomer, esketamine, exert both rapid and sustained antidepressant effects through activation of glutamate-related pathways, with neurotrophic effects involving BDNF, as demonstrated in experimental studies. However, clinical findings have shown mixed results, with most indicating an increase in plasma BDNF in patients treated with intravenous ketamine, although some studies contradict these findings. In addition to this, there are few studies of BDNF and esketamine. Currently, the limited number of studies suggests the need for further research, including larger sample sizes and investigations of BDNF and intranasal esketamine, which has been approved by several regulatory agencies for the treatment of treatment-resistant depression.

Overview

CoChat Summary

TL;DR

This narrative review summarizes evidence linking BDNF to the antidepressant mechanisms of ketamine and esketamine, emphasizing preclinical support for BDNF/TrkB-dependent neuroplasticity but mixed human clinical findings. It concludes that human data remain inconclusive, especially for esketamine and intranasal formulations, and calls for larger studies.

Key findings

  • Preclinical studies indicate ketamine’s rapid and sustained antidepressant effects require BDNF signaling: effects are blocked by anti-BDNF neutralizing antibody in the mPFC, BDNF or TrkB knockout models, and a selective TrkB inhibitor.
  • Human ketamine studies are mixed: some report increased plasma BDNF in responders, e.g., after 0.5 mg/kg IV ketamine at 240 min and at 230 min post-infusion, and in 53 healthy participants at 2 h and 24 h post-infusion; others report no increase in 23 TRD patients or in MDD patients at 230 min.
  • Esketamine human data are limited and mostly from special populations: IV esketamine 0.25 mg/kg increased plasma BDNF in postpartum depression at three days; IV esketamine 0.5 mg/kg reduced anxiety/depression with increased serum BDNF in thoracic surgery patients; in 417 cervical cancer surgery patients, 0.5 mg/kg IV esketamine produced greater BDNF increases than placebo, ketamine, or 0.25 mg/kg esketamine.
  • The review notes a 2021 analysis of 64 randomized controlled trials with 5299 participants found ketamine and esketamine may increase response and remission rates within 24 h versus placebo, but BDNF-specific human evidence remains limited.

Methods

  • Narrative review using PubMed, Scopus, and Google Scholar with keywords including “ketamine,” “esketamine,” “BDNF,” “neurotrophism,” and “neuroplasticity”; articles published in English were examined.
  • Preclinical studies were considered for molecular mechanisms linking ketamine/esketamine to BDNF, while human studies were reviewed for BDNF variations in patients treated with ketamine or esketamine.
  • No systematic review protocol, meta-analysis, or formal risk-of-bias assessment is described.

Limitations

  • The paper states that human studies are limited, often have small sample sizes, and show inconsistent results; the optimal timing for measuring BDNF remains unclear.
  • The paper states that few studies examine BDNF and esketamine, especially intranasal esketamine approved for TRD, and that no clinical studies have addressed long-term ketamine/esketamine effects on BDNF.
  • Evident from the text: as a narrative review, it does not systematically quantify study quality or pool effect sizes, and the included human studies are heterogeneous in populations, doses, routes, and BDNF measurement times.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms252313098

Cites

112 of 113 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Mechanisms of ketamine action involving brain-derived neurotrophic factor (BDNF). Ketamine acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor. The antagonism of NMDA receptors (NMDAR) is particularly important at the level of GABAergic interneurons (1), especially those expressing the GluN2b subunit. Indeed, this antagonism leads to a reduction in their activity, which normally inhibits glutamatergic pyramidal neurons (Glutamate Neurons). Consequently, the activity of these pyramidal neurons increases, leading to the release of glutamate, which primarily affects AMPA receptors (AMPAR) (A) and L-type voltage-dependent Ca2+ channels (L-VDCCs) (B), with a subsequent increase in the production of BDNF. Specifically, the activation of AMPAR leads to the phosphorylation of methyl CpG binding protein 2 (MeCP2), resulting in an increased transcription of genes such as BDNF. Additionally, NMDA receptor activation inhibits Eukaryotic elongation factor 2 (eEF2) kinase (2) (eEF2K), which normally phosphorylates eEF2, thereby inhibiting BDNF production. The dephosphorylation of eEF2 thus results in increased BDNF production. Furthermore, microglia (3) also play a role, with ketamine increasing the expression of Nuclear Receptor Binding Protein 1 (NRBP1) and phosphorylated cAMP response element-binding protein (CREB), leading to an increased transcription of BDNF. The increase in BDNF through these mechanisms stimulates the mammalian target of rapamycin complex 1 (mTORC1) signaling pathways, promoting increased protein synthesis and the formation of new dendritic spines. Additionally, this leads to the upregulation of hippocampal AMPAR subunits GluA1 and GluA2, and the activation of tropomyosin receptor kinase B (TrkB), which triggers intracellular pathways that contribute to synaptogenesis and the enhancement of NMDA receptor activity.
Figure 1 Mechanisms of ketamine action involving brain-derived neurotrophic factor (BDNF). Ketamine acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor. The antagonism of NMDA receptors (NMDAR) is particularly important at the level of GABAergic interneurons (1), especially those expressing the GluN2b subunit. Indeed, this antagonism leads to a reduction in their activity, which normally inhibits glutamatergic pyramidal neurons (Glutamate Neurons). Consequently, the activity of these pyramidal neurons increases, leading to the release of glutamate, which primarily affects AMPA receptors (AMPAR) (A) and L-type voltage-dependent Ca2+ channels (L-VDCCs) (B), with a subsequent increase in the production of BDNF. Specifically, the activation of AMPAR leads to the phosphorylation of methyl CpG binding protein 2 (MeCP2), resulting in an increased transcription of genes such as BDNF. Additionally, NMDA receptor activation inhibits Eukaryotic elongation factor 2 (eEF2) kinase (2) (eEF2K), which normally phosphorylates eEF2, thereby inhibiting BDNF production. The dephosphorylation of eEF2 thus results in increased BDNF production. Furthermore, microglia (3) also play a role, with ketamine increasing the expression of Nuclear Receptor Binding Protein 1 (NRBP1) and phosphorylated cAMP response element-binding protein (CREB), leading to an increased transcription of BDNF. The increase in BDNF through these mechanisms stimulates the mammalian target of rapamycin complex 1 (mTORC1) signaling pathways, promoting increased protein synthesis and the formation of new dendritic spines. Additionally, this leads to the upregulation of hippocampal AMPAR subunits GluA1 and GluA2, and the activation of tropomyosin receptor kinase B (TrkB), which triggers intracellular pathways that contribute to synaptogenesis and the enhancement of NMDA receptor activity.CC BY · PubMed Central
Figure 2 Binding of brain-derived neurotrophic factor (BDNF) to Tropomyosin Receptor Kinase B (TrkB) and the resulting neurotrophic mechanisms involved in depression. When BDNF binds to TrkB, it induces dimerization and autophosphorylation of its tyrosine kinase (1). This phosphorylation activates several intracellular signaling pathways (2), including the mammalian target of rapamycin complex 1 (mTORC1), phosphoinositide 3-kinase (PI3K), phospholipase C gamma (PLCγ), and mitogen-activated protein kinase (MAPK). These pathways regulate processes such as neuroplasticity, increasing cellular transcription and enhancing synaptogenesis (3). The importance of the BDNF-TrkB interaction for ketamine’s antidepressant action is highlighted by the fact that animal models treated with anti-BDNF antibodies, or knockout (KO) models for the BDNF or TrkB gene, or with selective TrkB inhibitors (TrkBi) (4), do not respond to ketamine’s antidepressant effects.
Figure 2 Binding of brain-derived neurotrophic factor (BDNF) to Tropomyosin Receptor Kinase B (TrkB) and the resulting neurotrophic mechanisms involved in depression. When BDNF binds to TrkB, it induces dimerization and autophosphorylation of its tyrosine kinase (1). This phosphorylation activates several intracellular signaling pathways (2), including the mammalian target of rapamycin complex 1 (mTORC1), phosphoinositide 3-kinase (PI3K), phospholipase C gamma (PLCγ), and mitogen-activated protein kinase (MAPK). These pathways regulate processes such as neuroplasticity, increasing cellular transcription and enhancing synaptogenesis (3). The importance of the BDNF-TrkB interaction for ketamine’s antidepressant action is highlighted by the fact that animal models treated with anti-BDNF antibodies, or knockout (KO) models for the BDNF or TrkB gene, or with selective TrkB inhibitors (TrkBi) (4), do not respond to ketamine’s antidepressant effects.CC BY · PubMed Central
Figure 3 Rapid and sustained mechanisms of ketamine and BDNF on synaptic plasticity.
Figure 3 Rapid and sustained mechanisms of ketamine and BDNF on synaptic plasticity.CC BY · PubMed Central

Verification

Claims the paper makes

86 Valid · 6 Not valid · 22 Not checked · 14 Own results and interpretations

65 more claims · 47 with their cited sources checked

Create a free account to see all 128 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 5
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 113 references

Cited by

See all 51

Metadata

Authors
Pardossi, S., Fagiolini, A., & Cuomo, A.
Affiliations
University of Siena (IT)
Corresponding author
Fagiolini, Andrea
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-12-05
Volume
25
Issue
23
Pages
13098
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4405031952
Cited by
51
References
113
Citations by year
2026: 28 · 2025: 23
FWCI
3.18
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
brain-derived neurotrophic factor, ketamine, esketamine, depression, antidepressant mechanism, neuroplasticity, glutamate pathway, treatment-resistant depression, plasma BDNF, intranasal esketamine, prefrontal cortex, hippocampus
MeSH terms
Animals, Antidepressive Agents, Depression, Humans, Ketamine, Brain-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review. https://app.cochat.ai/papers/10.3390/ijms252313098
The paper
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024). Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252313098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.